Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19291072 | 1.00 | HTR2C (0.70) | HTR2CDRD2MEN1KMT2ACA12 | |
| SCHEMBL7545433 | 0.96 | HTR2C (0.70) | HTR2CDRD2MEN1KMT2ACA12 | |
| SCHEMBL1428861 | 0.94 | HTR2C (0.68) | HTR2CDRD2MEN1KMT2AATM | |
| SCHEMBL6695552 | 0.94 | HTR2C (0.68) | HTR2CDRD2MEN1KMT2AATM | |
| SCHEMBL4736528 | 0.94 | HTR2C (0.68) | HTR2CDRD2MEN1KMT2AATM | |
| SCHEMBL30938438 | 0.94 | HTR2C (0.68) | HTR2CDRD2MEN1KMT2AATM | |
| SCHEMBL1515163 | 0.91 | HTR2C (0.75) | HTR2CDRD2MEN1KMT2ACA12 | |
| SCHEMBL14705093 | 0.84 | HTR2C (0.87) | HTR2CDRD2MEN1KMT2A | |
| SCHEMBL26918402 | 0.84 | HTR2C (0.57) | HTR2CDRD2MEN1KMT2ACA1 | |
| SCHEMBL8416024 | 0.84 | HTR2C (0.53) | HTR2CDRD2MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-115244037-B | Substituted triazinones as thyroid hormone receptor agonists | 诚益生物(美国)公司 | 2024-10-25 | — | — | CN | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| EP-4090652-A1 | SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS | Eccogene (Shanghai) Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-115244037-A | Substituted triazinones as thyroid hormone receptor agonists | 上海诚益生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | HTR2C 502/4885DRD2 2539/4885MEN1 510/4885 |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | HTR2C 502/4885DRD2 2539/4885MEN1 510/4885 |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | HTR2C 502/4885DRD2 2539/4885MEN1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.